Please wait while we load the requested 10-K report or click the link below:
Strongbridge Biopharma plc Reports Full-Year 2017 Financial Results
~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~
~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~
~ MACRILEN (macimorelin) Product Launch on Track for Mid-2018 ~
~ RECORLEV (levoketoconazole) Phase 3 Clinical Program Progressing with SONICS Top-line Results Expected in Mid-Year 2018 ~
~ Investor & Analyst Day in New York City Planned for April 5, 2018 to Discuss Clinical Development and Commercial Progress ~
Dublin, Ireland and Trevose, Pa., March 12, 2018 Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the full year and fourth quarter ended December 31, 2017.
2017 was a defining year for Strongbridge, marked by rapid transformation and growth as we became a revenue-generating rare disease company. As a result of the early launch uptake of KEVEYIS, the first and only FDA-approved treatment for Primary Periodic Paralysis (PPP), we made the decision to more than double our field-based team in the fourth quarter to meet growing market demand and position us for success in 2018 and beyond. This expanded investment reflects the significant opportunity in the market, the need to raise awareness of this ultra-rare disease and our commitment to patient communities, such as PPP, that may otherwise go ignored, said Matthew Pauls, president and chief executive officer of Strongbridge Biopharma.
In 2017, we completed enrollment in SONICS, our pivotal Phase 3 study of RECORLEV (levoketoconazole) in Cushings syndrome and look forward to top-line results in mid-2018. We are also excited to launch our second rare disease product, MACRILEN (macimorelin), in the middle of the year, Pauls added.
Full-Year 2017 Corporate & Financial Highlights
Early Launch Success with KEVEYIS Demonstrates Significant Market Opportunity:
· Achieved net product sales of $3.0 million during the fourth quarter of 2017, a 20% increase compared to $2.5 million in the third quarter.
The following information was filed by Strongbridge Biopharma Plc (SBBP) on Monday, March 12, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Strongbridge Biopharma Plc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Strongbridge Biopharma Plc.